Dr Reddy's Debuts Generic Antibiotic in US

Dr Reddy's Laboratories launches Doxycycline Capsules, a generic antibiotic, in the US market. The capsules are equivalent to Oracea capsules, approved by the USFDA. This launch expands Dr Reddy's portfolio of generic medications in the US. The company's shares rose on the news, ending 0.71% higher at Rs 6,332.85 per share on the BSE.

Dr Reddy's Laboratories on Friday said it has launched a generic medication, used to treat a wide variety of bacterial infections, in the US market.

The company has launched Doxycycline Capsules (40 mg) in the US market, the Hyderabad-based drug maker said in a statement.

The company's product is a therapeutic generic equivalent of Oracea capsules (40 mg) approved by the US Food and Drug Administration (USFDA).

Shares of the company on Friday ended 0.71 per cent up at Rs 6,332.85 apiece on the BSE.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)